Gene therapy trial offers hope for girls with rare brain disorder

NCT ID NCT06152237

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 21 times

Summary

This study tests a new gene therapy called TSHA-102 for girls aged 5 to 8 with Rett syndrome, a serious genetic disorder that affects brain development. The therapy is given as a single injection into the spinal fluid to try to improve symptoms. The main goal is to check safety, but researchers will also look for signs of improvement. The study is small (6 participants) and lasts up to 6 years, with close monitoring for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETT SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU Ste-Justine

    Montreal, Quebec, H3T 1C5, Canada

  • Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota, 55101, United States

  • Rush University Medical Center & Children's Hospital

    Chicago, Illinois, 60612, United States

  • Washington University, St. Louis

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.